According to a news release (published at timesunion.com; 4/10/12), plaintiff Gillian Gaghan used Accutane for six months in 1998. She allegedly developed inflammatory bowel disease six weeks after she discontinued the medication. Her lawsuit claimed Gaghan developed ulcerative colitis, which resulted in a loss of nighttime bowel control, and that had she known about the risks, she would not have used Accutane.
Gaghan's lawsuit was part of a consolidated lawsuit, involving two other plaintiffs, James Marshall and Kelly Andrews. Both Marshall and Andrews were denied an award, for different reasons.
Gaghan, however, was awarded $2 million in her lawsuit after the jury found that Accutane maker Hoffman-La Roche did not adequately warn patients about the risks associated with the medication and that use of Accutane could cause inflammatory bowel disease. Hoffman-La Roche appealed the jury's award.
Various studies have linked the use of isotretinoin (the generic version of Accutane) to inflammatory bowel disease such as ulcerative colitis. It has also been linked to a serious risk of birth defects.
READ MORE ACCUTANE IBD LEGAL NEWS
Inflammatory bowel disease is a potentially serious condition in which the patient's intestines become swollen, causing pain, cramping and, sometimes, bleeding. Some patients require surgery to remove a portion of their colon.
Accutane is no longer available on the market, although some generic versions are still being marketed.
In another recent Accutane lawsuit, the New Jersey Supreme Court ruled that Kamie Kendall did not miss the statute of limitations when she filed her lawsuit in 2005. She was awarded $10.5 million in her 2008, but Hoffman-La Roche appealed the award.